Latest Seattle Genetics (SGEN) Headlines
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Uptrend Call Working As Seattle Genetics Stock Rises 17.4% (SGEN)
Comtex SmarTrend(R) - Wed Mar 05, 9:52AM CST
SmarTrend identified an Uptrend for Seattle Genetics (NASDAQ:SGEN) on February 11th, 2014 at $45.31. In approximately 3 weeks, Seattle Genetics has returned 17.41% as of today's recent price of $53.20.
Seattle Genetics Presents Data on Adcetris - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 2:17PM CST
Seattle Genetics presented positive data on Adcetris at the 2014 Bone Marrow Transplant (BMT) Tandem Meeting.
Seattle Genetics Highlights ADCETRIS(R) (Brentuximab Vedotin) Clinical Data at the 2014 Bone Marrow Transplant Tandem Meetings
Business Wire - Thu Feb 27, 8:00AM CST
Seattle Genetics, Inc. (NASDAQ:SGEN) today highlighted ADCETRIS (brentuximab vedotin) data at the 2014 Bone Marrow Transplant (BMT) Tandem Meetings being held February 26 to March 2, 2014, in Dallas, Texas. Presentations included the first report from an ongoing phase 1/2 clinical trial evaluating the combination of ADCETRIS and bendamustine in the treatment of salvage Hodgkin lymphoma (HL). In addition, a poster presentation summarized the clinical trial design and pooled patient demographics from the phase 3 AETHERA trial in patients with increased risk factors for HL progression following autologous stem cell transplant (ASCT). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL).
Shares of SGEN Up 19.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 26, 9:17AM CST
SmarTrend identified an Uptrend for Seattle Genetics (NASDAQ:SGEN) on February 11th, 2014 at $45.31. In approximately 2 weeks, Seattle Genetics has returned 19.77% as of today's recent price of $54.27.
Insider Trading Alert - RKUS, POWI And SGEN Traded By Insiders
at The Street - Tue Feb 25, 10:30AM CST
Stocks with insider trader activity include RKUS, POWI and SGEN
Seattle Genetics Rises 3.19% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Feb 21, 5:18PM CST
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $53.26 to a high of $55.86. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $53.54 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Critical Alerts For Actavis, athenahealth, Seattle Genetics, JP Morgan Chase, and SodaStream Released By InvestorsObserver
PR Newswire - Wed Feb 19, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ACT, ATHN, SGEN, JPM, and SODA.
What You Need to Know About Seattle Genetics' Biggest Growth Driver
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 15, 8:30AM CST
It has been a very good year for Seattle Genetics and its investors. Sales of Adcetris posted solid results in its first full year on the market, and high-profile collaborations with AbbVie and Bayer helped the company's sales climb to $269...
3 Winning Stocks Warn of Biotech Bubble
David Williamson, The Motley Fool - Motley Fool - Wed Feb 12, 7:27PM CST
In this video from Wednesday's edition of Market Checkup , Motley Fool health-care analyst David Williamson takes investors through the biggest winners of the day in the biotech space. Seattle Genetics is first up on the list, coming in as a...
Why Seattle Genetics, TripAdvisor, and Freescale Semiconductor Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Feb 12, 7:01PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Stocks took a pause from their solid advances over the past...
Seattle Genetics Rises 10.72% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Feb 12, 4:55PM CST
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $47.13 to a high of $51.97. Yesterday, the shares gained 10.7%, which took the trading range above the 3-day high of $45.98 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Jim Cramer's 6 Stocks in 60 Seconds: BUD S LNG VJET SGEN CROX
at The Street - Wed Feb 12, 4:08PM CST
Cramer is disappointed by Crocs, thinks Cheniere is way ahead of the competition and would buy Anheuser-Busch ahead of earnings.
Why Seattle Genetics, Inc. Shares Soared
Alex Planes, The Motley Fool - Motley Fool - Wed Feb 12, 12:56PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Seattle Genetics are trading more than...
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 12, 12:33PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Why Seattle Genetics (SGEN) Hit An All-Time High Today
at The Street - Wed Feb 12, 10:54AM CST
Seattle Genetics (SGEN) soared to an all-time high of $51.97 on Wednesday morning after the biotech company announced a narrower-than-expected loss in its fourth-quarter results, along with revenues that surpassed analysts' expectations. The company...
Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 8:50AM CST
Seattle Genetics reported 4Q13 net loss per share of 13 cents, narrower than the Zacks Consensus Estimate of a loss of 24 cents.
Upgrade Alert for Seattle Genetics (SGEN)
Comtex SmarTrend(R) - Wed Feb 12, 7:57AM CST
Seattle Genetics (NASDAQ:SGEN) was upgraded from Hold to Buy at Needham today. The stock closed yesterday at $45.60 on volume of 1.0 million shares, above average daily volume of 876,000. In the past 52 weeks, Seattle Genetics share prices have been bracketed by a low of $26.60 and a high of $49.45 and closed yesterday at $45.60, 71% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.3% while the 50-day MA has advanced 0.5%.
Research and Markets: Future of Myanmar Oil Refinery Markets to 2020
Business Wire - Wed Feb 12, 6:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/wd86qs/future_of_myanmar) has announced the addition of the "Future of Myanmar Oil Refinery Markets to 2020- Outlook of Investments, Business Opportunities, Infrastructure, Petroleum Products, Supply- Demand and Competition" report to their offering.
Seattle Genetics posts higher net loss of USD62.5m in 2013
M2 - Wed Feb 12, 3:54AM CST
Biotechnology company Seattle Genetics Inc (NasdaqGS:SGEN) announced on Tuesday its net loss of USD62.5m (USD0.51 per share) for the year ended 31 December 2013.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Uptrend Call Working As Seattle Genetics Stock Rises 17.4% (SGEN)
Comtex SmarTrend(R) - Wed Mar 05, 9:52AM CST
SmarTrend identified an Uptrend for Seattle Genetics (NASDAQ:SGEN) on February 11th, 2014 at $45.31. In approximately 3 weeks, Seattle Genetics has returned 17.41% as of today's recent price of $53.20.
Seattle Genetics Presents Data on Adcetris - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 2:17PM CST
Seattle Genetics presented positive data on Adcetris at the 2014 Bone Marrow Transplant (BMT) Tandem Meeting.
Seattle Genetics Highlights ADCETRIS(R) (Brentuximab Vedotin) Clinical Data at the 2014 Bone Marrow Transplant Tandem Meetings
Business Wire - Thu Feb 27, 8:00AM CST
Seattle Genetics, Inc. (NASDAQ:SGEN) today highlighted ADCETRIS (brentuximab vedotin) data at the 2014 Bone Marrow Transplant (BMT) Tandem Meetings being held February 26 to March 2, 2014, in Dallas, Texas. Presentations included the first report from an ongoing phase 1/2 clinical trial evaluating the combination of ADCETRIS and bendamustine in the treatment of salvage Hodgkin lymphoma (HL). In addition, a poster presentation summarized the clinical trial design and pooled patient demographics from the phase 3 AETHERA trial in patients with increased risk factors for HL progression following autologous stem cell transplant (ASCT). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL).
Shares of SGEN Up 19.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 26, 9:17AM CST
SmarTrend identified an Uptrend for Seattle Genetics (NASDAQ:SGEN) on February 11th, 2014 at $45.31. In approximately 2 weeks, Seattle Genetics has returned 19.77% as of today's recent price of $54.27.
Insider Trading Alert - RKUS, POWI And SGEN Traded By Insiders
at The Street - Tue Feb 25, 10:30AM CST
Stocks with insider trader activity include RKUS, POWI and SGEN
Seattle Genetics Rises 3.19% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Feb 21, 5:18PM CST
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $53.26 to a high of $55.86. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $53.54 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Critical Alerts For Actavis, athenahealth, Seattle Genetics, JP Morgan Chase, and SodaStream Released By InvestorsObserver
PR Newswire - Wed Feb 19, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ACT, ATHN, SGEN, JPM, and SODA.
What You Need to Know About Seattle Genetics' Biggest Growth Driver
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 15, 8:30AM CST
It has been a very good year for Seattle Genetics and its investors. Sales of Adcetris posted solid results in its first full year on the market, and high-profile collaborations with AbbVie and Bayer helped the company's sales climb to $269...
3 Winning Stocks Warn of Biotech Bubble
David Williamson, The Motley Fool - Motley Fool - Wed Feb 12, 7:27PM CST
In this video from Wednesday's edition of Market Checkup , Motley Fool health-care analyst David Williamson takes investors through the biggest winners of the day in the biotech space. Seattle Genetics is first up on the list, coming in as a...
Why Seattle Genetics, TripAdvisor, and Freescale Semiconductor Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Feb 12, 7:01PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Stocks took a pause from their solid advances over the past...
Seattle Genetics Rises 10.72% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Feb 12, 4:55PM CST
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $47.13 to a high of $51.97. Yesterday, the shares gained 10.7%, which took the trading range above the 3-day high of $45.98 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Jim Cramer's 6 Stocks in 60 Seconds: BUD S LNG VJET SGEN CROX
at The Street - Wed Feb 12, 4:08PM CST
Cramer is disappointed by Crocs, thinks Cheniere is way ahead of the competition and would buy Anheuser-Busch ahead of earnings.
Why Seattle Genetics, Inc. Shares Soared
Alex Planes, The Motley Fool - Motley Fool - Wed Feb 12, 12:56PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Seattle Genetics are trading more than...
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 12, 12:33PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Why Seattle Genetics (SGEN) Hit An All-Time High Today
at The Street - Wed Feb 12, 10:54AM CST
Seattle Genetics (SGEN) soared to an all-time high of $51.97 on Wednesday morning after the biotech company announced a narrower-than-expected loss in its fourth-quarter results, along with revenues that surpassed analysts' expectations. The company...
Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 8:50AM CST
Seattle Genetics reported 4Q13 net loss per share of 13 cents, narrower than the Zacks Consensus Estimate of a loss of 24 cents.
Upgrade Alert for Seattle Genetics (SGEN)
Comtex SmarTrend(R) - Wed Feb 12, 7:57AM CST
Seattle Genetics (NASDAQ:SGEN) was upgraded from Hold to Buy at Needham today. The stock closed yesterday at $45.60 on volume of 1.0 million shares, above average daily volume of 876,000. In the past 52 weeks, Seattle Genetics share prices have been bracketed by a low of $26.60 and a high of $49.45 and closed yesterday at $45.60, 71% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.3% while the 50-day MA has advanced 0.5%.
Research and Markets: Future of Myanmar Oil Refinery Markets to 2020
Business Wire - Wed Feb 12, 6:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/wd86qs/future_of_myanmar) has announced the addition of the "Future of Myanmar Oil Refinery Markets to 2020- Outlook of Investments, Business Opportunities, Infrastructure, Petroleum Products, Supply- Demand and Competition" report to their offering.
Seattle Genetics posts higher net loss of USD62.5m in 2013
M2 - Wed Feb 12, 3:54AM CST
Biotechnology company Seattle Genetics Inc (NasdaqGS:SGEN) announced on Tuesday its net loss of USD62.5m (USD0.51 per share) for the year ended 31 December 2013.
